StockDuty ← Dashboard Oct 24, 2026 03:23 PM ET
SignalFDA/Bio

Moderna’s cancer vaccine is ‘likely’ to get approved. Skeptics question if it will be the best option.

Moderna's cancer vaccine focus shifts to long-term recurrence prevention versus Keytruda efficacy.

What happened: Moderna's first Phase 3 data for a cancer vaccine has raised questions about whether the potential new treatment is needed. Why it matters: The article frames the real test as whether the vaccine keeps cancer from coming back in the long term, rather than beating Keytruda. Coverage: 5 outlets in 24h
Moderna's first Phase 3 data for a cancer vaccine has raised questions about whether the potential new treatment is needed.
The article frames the real test as whether the vaccine keeps cancer from coming back in the long term, rather than beating Keytruda.
Sources